echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > BMS finds new territory for its multiple sclerosis drug Zeposia

    BMS finds new territory for its multiple sclerosis drug Zeposia

    • Last Update: 2021-06-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 27, 2021, the FDA approved Bristol-Myers-Squibb's multiple sclerosis drug Zeposia for the treatment of moderate to severe active ulcerative colitis (UC).


    Achieving this transition requires some commercial operations, and there is a general price gap between MS and UC drugs.


    At present, various types of bioinjectable preparations are in a leading position in the UC market, including tumor necrosis factor inhibitors, such as AbbVie's Humira; Takeda's Entyvio; Johnson & Johnson's IL-12/23 antibody.


    Zeposia proved its value in UC in the Phase 3 True North study.


    Zeposia will also compete with Pfizer Pfizer's oral JAK inhibitor Xeljanz.


    Although Zeposia is now the first S1P drug to enter UC, competition is brewing.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.